|
Median Technologies, a French-based company of AI-powered software as a medical device (SaMD) for early cancer diagnosis and also a provider of artificial intelligence-enhanced and central imaging services for oncology drug developers, has announced its non-exclusive distribution agreement with Tempus AI, Inc, a technology company leading the adoption of artificial intelligence to advance precision medicine.
The collaboration follows the US Food and Drug Administration 510(k) clearance for Eyonis LCS and aims to integrate high-performance lung cancer screening detection and diagnosis device into the clinical workflow through the Tempus Pixel platform.
Under the agreement, Tempus AI will distribute Eyonis LCS to United States imaging providers through the Tempus Pixel platform and support implementation, customer onboarding, and workflow integration.
Tempus Pixel is a US Food and Drug Administration-cleared, CE-marked artificial intelligence-enabled solution that offers advanced analysis, tools, and automated reporting from radiology images to help providers accurately track and quantify lesions. It aims to aid providers in making informed diagnostic and disease management decisions.
Median Technologies announced on February 9, 2026, that Eyonis LCS, its artificial intelligence-based CADe/CADx Software as a Medical Device (SaMD) for lung cancer screening has received US Food and Drug Administration 510(k) clearance. Eyonis LCS is the only device capable of detecting and characterizing lung cancer in low-dose CT scans (LDCT), with 93.3 per cent sensitivity, 92.4 per cent specificity, and 99.9 per cent Negative Predictive Value (NPV) (manufacturer values calculated on a lung cancer screening reference population), helping clinicians identify suspicious findings earlier and improve the efficiency and consistency of lung cancer screening programmes.
Fredrik Brag, CEO and founder of Median Technologies stated: “Activating our distribution collaboration with Tempus artificial intelligence is a decisive step in bringing Eyonis LCS to patients at national scale. Tempus AI’s strong leadership in artificial intelligence-enabled precision medicine, deeply integrated data-technology ecosystem, and strong market presence make them an exceptional partner to drive rapid and high-impact adoption of Eyonis LCS across the United States.”
Razik Yousfi, Tempus SVP & GM, artificial intelligence products added: “We believe artificial intelligence reaches its full potential when it helps clinicians identify disease earlier and more accurately. By expanding our Pixel platform with sophisticated lung cancer screening AI tools, we are enabling radiologists to manage complex caseloads while prioritizing early-stage detection. Our collaboration with Median Technologies is about more than technology; it’s about improving the standard of care and preventing avoidable deaths through better screening access.”
Revenues generated from the use of Eyonis LCS will be shared between the parties in accordance with the commercial terms of the partnership. The collaboration builds on the existing NT-APC 1508 reimbursement pathway ($601–$700) and targets the 14.5 million Americans eligible for lung cancer screening.
Median continues to progress along the European regulatory pathway for Eyonis LCS and anticipates obtaining CE marking in Q2 2026. Under the executed distribution agreement, Tempus AI would support the commercial rollout of Eyonis LCS across Europe.
Median Technologies announced the signature of the non-exclusive distribution agreement on December 8, 2025, without disclosing the partner’s identity.
Median Technologies is a pioneer in innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge artificial intelligence to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and Eyonis, an artificial intelligence/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies.
|